Optimizing the use of cyclosporin in allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 38, Issue 3, 2006, Pages 169-174

  Duncan, Nick ^a   Craddock, C ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MACROLIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MONITORING; DRUG USE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; TREATMENT OUTCOME;

CYCLOSPORINE; DRUG MONITORING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33746285509     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705404     Document Type: Review

References (65)

1. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 16: 327-329.
2. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukaemia: Long-term follow up of a controlled trial. Blood 1989; 73: 1729-1734.
3. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
4. Nash RA, Antin JA, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation. Blood 2000; 96: 2062-2068.
5. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181-185.
6. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625.
7. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor malignancies. Blood 2003; 102: 1601-1605.
8. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplantation 2004; 10: 328-336.
9. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759-764.
10. Duncan N. A survey of practice relating to the dosing, administration and monitoring of i.v. ciclosporin in UK haematology centers. British Oncology Pharmacy Association Annual Symposium; Birmingham, 2004.
11. Bacigalupo A, Van Lint MT, Occhini D, Gualandi T, Lamparelli T, Sogno E et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukaemia. Blood 1991; 77: 1423-1428.
12. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola A, di Grazia C et al. Increased risk of leukaemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukaemia: 10-year follow-up of a randomized study. Blood 2001; 98: 3174-3175.
13. Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM et al. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant 1998; 22: 541-545.
14. Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allongeneic peripheral blood stem cell transplantation. Haematologica 2003; 88: 315-323.
15. Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995; 86: 4376-4381.
16. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
17. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; ii: 1323.
18. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
19. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
20. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of ciclosporin. Clin Pharmacokinetics 1986; 11: 107-132.
21. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004; 36 (S1): S378-S391.
22. Wood AJ, Maurer G, Neiderberger W, Beveridge T. Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc 1983; 15: 2409-2412.
23. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, Concannon A et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplantation: Implications of clinical gut dysfunction. Br J Haematol 1984; 56: 223-231.
24. Yee GC, Lennon TP, Gmur DG, Carlin J, Schaffer RL, Kennedy MS et al. Clinical pharmacology of cyclosporine in patients undergoing bone marrow transplantation. Transplant Proc 1986; 18: 153-159.
25. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 1984; 18: 887-893.
26. Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327-329.
27. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014-1018.
28. Ptachcinski RJ, Carpenter BJ, Burckhart GJ, Venkataramanan R, Rosenthal JT. Effect of erythromycin on cyclosporine levels. N Engl J Med 1985; 313: 1416-1417.
29. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997; 43: 194-196.
30. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36: 420S-425S.
31. Schmidt H, Ehninger G, Dopfer R, Blaurock M, Naumann R, Einsele H et al. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation. Blut 1988; 57: 139-142.
32. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65-70.
33. Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK et al. Cyclosporine and methyl-prednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 1991; 7: 461-465.
34. Ghalie R, Fitzsimmons WE, Weinstein A, Manson S, Kaizer H. Cyclosporine monitoring improves graft-versus-host-disease prophylaxis after bone marrow transplantation. Ann Pharmacother 1994; 28: 379-383.
35. Barrett AJ, Kendra JR, Lucas CF, Joss DV, Joshi R, Pendharkar P et al. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. BMJ (Clin Res Ed) 1982; 285: 162-166.
36. Gratwohl A, Speck B, Wenk M, Forster I, Muller M, Osterwalder B et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease and nephrotoxicity. Transplantation 1983; 36: 40-4.
37. Bacigalupo A, Di Georgio F, Frassoni F, VanLint MT, Raffo MR, Gogioso L et al. Cyclosporin A serum and blood levels in marrow graft recipients: correlation with administered dose, serum creatinine and graft-versus host disease. Acta Haematol 1984; 72: 155-162.
38. Kennedy Ms, Yee GC, McGuire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentrations with renal dysfunction in marrow transplant recipients. Transplantation 1985; 40: 249-253.
39. Yee GC, Kennedy MS, Gmur DJ, Self SG, Deeg HJ. Monitoring cyclosporin concentrations in marrow transplant recipients: Comparison of two assay methods. Bone Marrow Transplant 1987; 1: 289-295.
40. Kahan BD, Wideman CA, Reid M, Gibbons S, Jarowenko M, Flechner S et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc 1984; 16: 1195-1199.
41. Holt DW, Marsden JT, Johnston A, Bewick M, Taube DH. Blood cyclosporin concentrations and renal allograft dysfunction. BMJ (Clin Res Ed) 1986; 293: 1057-1059.
42. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994; 58: 989-996.
43. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631-644.
44. White D, Rose M, Wright L, Wallwork J, English TA, Hakim M et al. Failure of whole blood cyclosporine levels to provide a reliable measure of immunosuppression in clinical heart and heart/lung transplantation. Transplant Proc 1988; 20: 422-425.
45. Henry ML, Bowers VD, Fanning WJ, Sommer BG, Ferguson RM. Cyclosporine levels are not helpful. Transplant Proc 1988; 20: 419-421.
46. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 55-62.
47. max) correlate with freedom from liver graft rejection. Transplantation 1999; 67: 1133-1137.
48. Cantarovich M, Barkun JS, Tchervenkov J, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine trough levels versus 2-hr post dose levels in stable liver transplant patients. Transplantation 1998; 66: 1621-1627.
49. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157-166.
50. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486.
51. Grevel J, Walsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11: 246-248.
52. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentration and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
53. Meyer MM, Munar M, Udeaja J, Bennett W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993; 4: 1306-1315.
54. Johnston A. Sparse-sampling - a practical method for measurement of AUCs. Focus on Med 1998; 13: 7-10.
55. Johnston A, Sketris I, Marsden JT, Galustian CG, Fashola T, Taube D et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990; 22: 1345-1346.
56. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplantation 1998; 12: 243-249.
57. Levy G. Two-hour cyclosporin concentration (C2) as a monitoring tool for Neoral. Focus on Med 1998; 13: 19-22.
58. Cantarovich M, Elstein E, De Varennes D, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68: 1839-1842.
59. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-1032.
60. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953-959.
61. 2 monitoring: An international consensus statement. Transplantation 2002; 73: S12-S18.
62. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Therap Drug Monitor 2002; 24: 59-67.
63. Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporin A. Blood 1994; 84: 3974-3979.
64. Sanquer S, Schwarzinger M, Maury S, Yakouben K, Rafi H, Pautas C et al. Calcineurin activity as a therapeutic index of immunosuppression: A functional, pharmacodynamic approach for GVHD prophylaxis. Transplantation 2004; 77: 854-858.
65. Delaney MP, Smythe E, Higgins RM, Morris AG. Constitutive and acquired resistance to calcineurin inhibitors in renal transplantation: Role of P-glycoprotein-170. Transpl Int 2000; 13: 276-284.